<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00853970</url>
  </required_header>
  <id_info>
    <org_study_id>CL-S&amp;E-1205081-P</org_study_id>
    <nct_id>NCT00853970</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch &amp; Lomb Incorporated</source>
  <brief_summary>
    <textblock>
      Efficacy study of Bromfenac Ophthalmic Solution in cataract surgery
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Summed Ocular Inflammation Score (SOIS) of Zero</measure>
    <time_frame>Day 15 (Primary Endpoint)</time_frame>
    <description>Participants with SOIS of 0. Measured on a scale of 0-4: 0=0 cells (complete absence); 0.5=1-5 cells ; 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=&gt;50 cells (intense)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Free</measure>
    <time_frame>Day 1</time_frame>
    <description>Participants that are pain free at day 1, taken from patient questionnaire with multiple possible responses measured on a scale of 0-3, where 0=none and 3=severe.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">299</enrollment>
  <condition>Pain</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Bromfenac ophthalmic solution 0.09%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>dosed 1 drop daily in study eye for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>dosed 1 drop daily in study eye for 2 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromfenac Ophthalmic Solution</intervention_name>
    <description>sterile ophthalmic solution</description>
    <arm_group_label>Bromfenac ophthalmic solution 0.09%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Comparator</intervention_name>
    <description>sterile ophthalmic solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female at least 18 years of age who are scheduled for unilateral cataract
             surgery

        Exclusion Criteria:

          -  Have known hypersensitivity to bromfenac or to any component of the investigational
             product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tim McNamara, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>ISTA Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISTA Pharmaceuticals, Inc.</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2009</study_first_submitted>
  <study_first_submitted_qc>February 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2009</study_first_posted>
  <results_first_submitted>November 15, 2010</results_first_submitted>
  <results_first_submitted_qc>January 7, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 26, 2011</results_first_posted>
  <disposition_first_submitted>November 15, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>January 7, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 26, 2011</disposition_first_posted>
  <last_update_submitted>January 11, 2013</last_update_submitted>
  <last_update_submitted_qc>January 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain and Inflammation as a function of cataract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Bromfenac</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first participant entered the study on 02/09/2009, and last participant exited the study on 07/06/2009. This study took place at 41 sites in the USA</recruitment_details>
      <pre_assignment_details>152 participants were randomized to the bromfenac ophthalmic solution 0.09% treatment group and 147 were randomized to the placebo treatment group. One hundred forty six of 152 participants (96.1%) in the bromfenac ophthalmic solution 0.09% treatment group and 144/147 (98.0%) participants in the placebo treatment group completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Bromfenac Ophthalmic Solution 0.09%</title>
          <description>dosed 1 drop daily into the study eye for 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>dosed 1 drop daily into the study eye for 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
                <participants group_id="P2" count="147"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="144"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Cancelled surgery</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bromfenac Ophthalmic Solution 0.09%</title>
          <description>one drop daily in study eye for 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>one drop daily in study eye for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="152"/>
            <count group_id="B2" value="147"/>
            <count group_id="B3" value="299"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.4" lower_limit="34.0" upper_limit="87.0"/>
                    <measurement group_id="B2" value="69.1" lower_limit="40.0" upper_limit="90.0"/>
                    <measurement group_id="B3" value="69.8" lower_limit="34.0" upper_limit="90.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Summed Ocular Inflammation Score (SOIS) of Zero</title>
        <description>Participants with SOIS of 0. Measured on a scale of 0-4: 0=0 cells (complete absence); 0.5=1-5 cells ; 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=&gt;50 cells (intense)</description>
        <time_frame>Day 15 (Primary Endpoint)</time_frame>
        <population>Last observation carried forward (LOCF) Analysis; Intent to treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bromfenac Ophthalmic Solution 0.09%</title>
            <description>one drop daily in study eye for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one drop daily in study eye for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Summed Ocular Inflammation Score (SOIS) of Zero</title>
          <description>Participants with SOIS of 0. Measured on a scale of 0-4: 0=0 cells (complete absence); 0.5=1-5 cells ; 1=6-15 cells (very slight); 2=16-25 cells (moderate); 3=26-50 cells (marked); 4=&gt;50 cells (intense)</description>
          <population>Last observation carried forward (LOCF) Analysis; Intent to treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Free</title>
        <description>Participants that are pain free at day 1, taken from patient questionnaire with multiple possible responses measured on a scale of 0-3, where 0=none and 3=severe.</description>
        <time_frame>Day 1</time_frame>
        <population>Last observation carried forward (LOCF) Analysis, Intent to treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>Bromfenac Ophthalmic Solution 0.09%</title>
            <description>one drop daily in study eye for 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>one drop daily in study eye for 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Free</title>
          <description>Participants that are pain free at day 1, taken from patient questionnaire with multiple possible responses measured on a scale of 0-3, where 0=none and 3=severe.</description>
          <population>Last observation carried forward (LOCF) Analysis, Intent to treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
                <count group_id="O2" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Bromfenac Ophthalmic Solution 0.09%</title>
          <description>one drop daily in study eye for 2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>one drop daily in study eye for 2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Acute and chronic pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Eye and ear procedural complications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (8.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="147"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Eye Pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E2" events="37" subjects_affected="34" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Eye Inflammation</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E2" events="22" subjects_affected="21" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Foreign body sensation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="147"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="147"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Ocular Hyperemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="147"/>
                <counts group_id="E2" events="18" subjects_affected="15" subjects_at_risk="144"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="147"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="144"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The disclosure restriction on the PI is that the PI will provide to the sponsor a copy of proposed publication information for review, comment and approval following completion of the study and at least sixty (60) days prior to submission of the publication. If sponsor requests in writing, the PI will withhold publication until written permission is given by Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tim McNamara, Vice President, Clinical Research &amp; Medical Affairs</name_or_title>
      <organization>ISTA Pharmaceuticals, Inc.</organization>
      <phone>949-788-6000</phone>
      <email>tmcnamara@istavision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

